End of May 2020, as the COVID-19 pandemic continued to hold the world’s healthcare systems and economies in its grip, Argenx was one of the Brussels stock market’s favorites. The biotech firm from Ghent (Flanders) had just announced its excellent research results for efgartigimod, an antibody fragment that’s being evaluated for the treatment of patients with severe autoimmune diseases such as neuromuscular disease myasthenia gravis (MG). Commercialization of the medicine is now within reach, boosting the company’s market value by 30% to reach EUR 8 billion.
“The bar was set very high and our medicine ‘jumped over it’ smoothly,” says Tim Van Hauwermeiren, CEO of Argenx. “Two-thirds of the patients experienced fewer complaints thanks to the medicine, and 40% stated that they have no or minimal complaints. That, of course, is the main goal: enable patients to live their lives without being constantly reminded of their disease. It’s fantastic news.”